Based on the key indicators related to Lyra Therapeutics' liquidity, profitability, solvency, and operating efficiency, Lyra Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December. At present, Lyra Therapeutics' Total Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Other Liabilities is expected to grow to about 17 M, whereas Total Assets are forecasted to decline to about 78.6 M. Key indicators impacting Lyra Therapeutics' financial strength include:
The financial analysis of Lyra Therapeutics is a critical element in measuring its lifeblood. Investors should not minimize Lyra Therapeutics' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income
(59.55 Million)
Lyra
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Cash Ratio
Operating Cash Flow Sales Ratio
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Price Fair Value
Return On Equity
Sale Purchase Of Stock
Investments
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Operating Activities
Issuance Of Capital Stock
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Other Liab
Net Tangible Assets
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Cash And Short Term Investments
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Capital Surpluse
Capital Lease Obligations
Other Current Assets
Other Stockholder Equity
Total Liab
Net Invested Capital
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Capital Stock
Net Working Capital
Common Stock
Property Plant Equipment
Short Long Term Debt Total
Current Deferred Revenue
Short Term Debt
Net Interest Income
Interest Income
Depreciation And Amortization
Interest Expense
Selling General Administrative
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Total Operating Expenses
Reconciled Depreciation
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Cost Of Revenue
Probability Of Bankruptcy
Understanding current and past Lyra Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Lyra Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Lyra Therapeutics' assets may result in an increase in income on the income statement.
Please note, the presentation of Lyra Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Lyra Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Lyra Therapeutics' management manipulating its earnings.
Lyra Therapeutics Stock Summary
Lyra Therapeutics competes with Eliem Therapeutics, HCW Biologics, Scpharmaceuticals, Milestone Pharmaceuticals, and Seres Therapeutics. Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts. Lyra Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 60 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Lyra Therapeutics's current stock value. Our valuation model uses many indicators to compare Lyra Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lyra Therapeutics competition to find correlations between indicators driving Lyra Therapeutics's intrinsic value. More Info.
Lyra Therapeutics is rated fifth overall in return on equity category among its peers. It also is rated fifth overall in return on asset category among its peers . At present, Lyra Therapeutics' Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lyra Therapeutics' earnings, one of the primary drivers of an investment's value.
Lyra Therapeutics Systematic Risk
Lyra Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Lyra Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Lyra Therapeutics correlated with the market. If Beta is less than 0 Lyra Therapeutics generally moves in the opposite direction as compared to the market. If Lyra Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Lyra Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Lyra Therapeutics is generally in the same direction as the market. If Beta > 1 Lyra Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Lyra Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Lyra Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Lyra Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio
0.14
At present, Lyra Therapeutics' Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting.
Lyra Therapeutics November 26, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Lyra Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Lyra Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Lyra Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Lyra Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Lyra Therapeutics's daily price indicators and compare them against related drivers.
When running Lyra Therapeutics' price analysis, check to measure Lyra Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lyra Therapeutics is operating at the current time. Most of Lyra Therapeutics' value examination focuses on studying past and present price action to predict the probability of Lyra Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lyra Therapeutics' price. Additionally, you may evaluate how the addition of Lyra Therapeutics to your portfolios can decrease your overall portfolio volatility.